Atlas Trials

A Phase I First-in-Human Study of GenSci128 in Patients With Solid Tumors Harboring a TP53 Y220C Mutation

Clinical trial NCT06908434 · RECRUITING

Trial details

NCT number
NCT06908434
Sponsor
Changchun GeneScience Pharmaceutical Co., Ltd.
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Solid Tumors Harboring a TP53 Y220C Mutation
Start date
2025-06-10
Primary completion
2027-12-01
Enrollment
82

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.